Back to Search Start Over

Renowned Researcher Dr. Russell Lonser will Lead DeepWell DTx and NeuFluent Pharmaceutical Technology Program

Source :
PR Newswire. October 1, 2024
Publication Year :
2024

Abstract

DeepWell Digital Therapeutics (DTx), which commercializes immersive medical media, and NeuFluent, its venture studio that develops neuroscience innovation, together announce that Dr. Russell Lonser will serve as the companies' global [...]

Subjects

Subjects :
United States. Food and Drug Administration
Nonprescription drugs
Program development software
Neurosciences
Hypertension -- Care and treatment
Application installation/distribution software
Application development software
Business
News, opinion and commentary

Details

Language :
English
Database :
Gale General OneFile
Journal :
PR Newswire
Publication Type :
News
Accession number :
edsgcl.810716716

Tools

Authors Abstract Subjects Details